NIH-funded research R01 grant

Understanding how sugar modifications affect a protein involved in various diseases

Official title: N-glycosylation as a regulator of Grp94 Function and Activity

Funded at Hauptman-Woodward Medical Research Inst · NIH-10780544 · Data updated 2026-11-12

This study is looking at how sugar changes on a protein called Grp94 can affect its ability to help other proteins work properly, which could lead to new ways to treat chronic conditions like type 2 diabetes and some cancers, ultimately helping patients get better care.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionHauptman-Woodward Medical Research Inst
NIH-funded
Lab location1 site (Buffalo, United States)
Project startSeptember 1, 2024
Project endAugust 31, 2028
Funding year2024
Award (this year)$388,000
NIH project number1R01GM152842-01
Project IDNIH-10780544 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research include individuals with type 2 diabetes, familial hypercholesterolemia, or specific types of cancer such as HER2-positive breast cancer.

Less likely to help

Patients with acute conditions unrelated to protein folding or those not affected by the diseases being studied may not receive any benefit from this research.

What this research studies

This research investigates the role of N-glycosylation in regulating the function of Grp94, a protein that assists in the proper folding and maturation of other proteins within the endoplasmic reticulum. By examining how changes in sugar modifications on Grp94 influence its activity, the research aims to uncover new therapeutic targets for chronic diseases such as type 2 diabetes and certain cancers. Patients may benefit from insights gained about how Grp94's function can be manipulated to improve treatment outcomes. The approach includes biochemical assays and advanced imaging techniques to analyze protein behavior under different conditions.

Why it matters

Potential benefit: If successful, this research could lead to new treatments for chronic diseases by targeting the mechanisms that regulate protein folding and function.

How similar studies have gone: Previous research has shown promising results in targeting protein chaperones for therapeutic purposes, indicating that this approach may yield significant advancements.

Where this research is happening

  • Hauptman-Woodward Medical Research Inst
    Buffalo, United States
    Active

Researchers

  • Principal investigator: Gewirth, Daniel T — Hauptman-Woodward Medical Research Inst
  • Study coordinator: Gewirth, Daniel T

Related research

Other NIH-funded projects on the same topics.

  • New methods for detecting tiny crystals in biological research

    This study is exploring new ways to see and work with tiny crystal samples of biomolecules, which are important for learning about diseases and finding new treatments, so we can better understand how these molecules affect our health.

    NIH research Hauptman-Woodward Medical Research Inst · Buffalo, United States · NIH-10914998

  • Improving methods to crystallize biological macromolecules for better structural analysis

    This study is working on better ways to grow crystals from important biological molecules, which helps scientists understand how these molecules work, and this could eventually lead to new treatments and a better understanding of diseases for patients like you.

    NIH research Hauptman-Woodward Medical Research Inst · Buffalo, United States · NIH-10887482

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.